newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Grants of Inducement Awards

  • Crescent Biopharma's Compensation Committee approved equity inducement awards totaling 52,500 option shares for two non-executive employees on July 22, 2026.
  • The grants were made under the 2025 Employment Inducement Incentive Award Plan & are material to the employees' acceptance of employment per Nasdaq Listing Rule 5635(c)(4).
  • Each option has a 10-year term with an exercise price of $15.83, based on the July 22, 2026 closing price.
  • Vesting schedules include one-fourth of the shares upon the first anniversary of the start date, with one-forty-eighth vesting monthly thereafter subject to continuous service.
  • Crescent Biopharma is a clinical-stage oncology company focusing on a PD-1 x VEGF bispecific antibody & novel antibody-drug conjugates for solid tumors.